- Two patients exhibited an unconfirmed partial response at their first scan, and two additional patients saw promising tumor regression activity out of.
Rain Therapeutics Inc. (NASDAQ:NASDAQ:RAIN) Q1 2022 Results Conference Call May 04, 2022 05:00 PM ET Company Participants Bob Yedid - LifeSci Advisors Avanish Vellanki - CEO Robert Doebele.